SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements
16 references·0 citing·33 second hop
The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements (2024)The pharmaceutical productivity gap – Inc…How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)How Much Does It Cost to Rese…A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions (2021)A Decade of FDA-Approved Drug…Trends in clinical success rates (2016)Trends in clinical success ra…Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Innovation in the pharmaceuti…New drugs cost US$2.6 billion to develop (2014)New drugs cost US$2.6 billion…Risk in Vaccine Research and Development Quantified (2013)Risk in Vaccine Research and …Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)Drug discovery in pharmaceuti…Diagnosing the decline in pharmaceutical R&D efficiency (2012)Diagnosing the decline in pha…The productivity crisis in pharmaceutical R&D (2011)The productivity crisis in ph…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…Deconstructing the Drug Development Process: The New Face of Innovation (2010)Deconstructing the Drug Devel…Lessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Mergers and acquisitions in the pharmaceutical and biotech industries (2007)Mergers and acquisitions in t…The myth of the biotech revolution (2004)The myth of the biotech revol…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …The Human Genome Project: Lessons from Large-Scale Biology (2003)The Human Genome Project: Les…Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The black swan: the impact of the highly improbable (2007)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Can the pharmaceutical industry reduce attrition rates? (2004)Mitigating risk in academic preclinical drug discovery (2015)The changing model of big pharma: impact of key trends (2015)Exploring the impact of open innovation on firm performances (2016)Risks in new drug development: Approval success rates for investigational drugs (2001)The cost of biopharmaceutical R&D: is biotech different? (2007)Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)Exploring different approaches to improve the success of drug discovery and development projects: a review (2020)The past, present and future of open innovation (2020)The Common Thread (2002)The Human Genome Project: A Player's Perspective (2002)Health metrics and evaluation: strengthening the science (2008)The Economics of Science (2010)Handbook of Self-Regulation of Learning and Performance (2017)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)Cost of innovation in the pharmaceutical industry (1991)Stocks, bonds, bills, and inflation yearbook (1993)Clinical development success rates for investigational drugs (2014)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)Cost-Effectiveness in Health and Medicine (1996)Essential medicines for universal health coverage (2016)The High Cost of Prescription Drugs in the United States (2016)Are Ideas Getting Harder to Find? (2020)Generating Theory by Abduction (2021)R&D Costs of New Medicines: A Landscape Analysis (2021)Analysis of pharma R&D productivity – a new perspective needed (2023)Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 (2024)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,312 cited
  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,686 cited
  • 2016Innovation in the pharmaceutical industry: New estimates of R&D costs3,621 cited
  • 2012Diagnosing the decline in pharmaceutical R&D efficiency2,039 cited
  • 2003The Human Genome Project: Lessons from Large-Scale Biology1,284 cited
  • 2009Lessons from 60 years of pharmaceutical innovation1,238 cited
  • 2011The productivity crisis in pharmaceutical R&D918 cited
  • 2012Drug discovery in pharmaceutical industry: productivity challenges and trends478 cited
  • 2010Deconstructing the Drug Development Process: The New Face of Innovation422 cited
  • 2021How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment360 cited
  • 2021A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions323 cited
  • 2016Trends in clinical success rates277 cited
  • 2004The myth of the biotech revolution260 cited
  • 2013Risk in Vaccine Research and Development Quantified253 cited
  • 2007Mergers and acquisitions in the pharmaceutical and biotech industries

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

236 cited
  • 2014New drugs cost US$2.6 billion to develop217 cited
  • Cited by

    No citing works inside the corpus for this window.